Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is the best buy from here?

Eli Lilly’s stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation.